NICE
Boehringer gets NICE nod for Pradaxa
December 16, 2014Sales and Marketing Boehringer, NHS, NICE, Pradaxa, VTE, dagibatran, ingelheim, warfarin
NICE has confirmed a recommendation for Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa, as a treatment for blood clots in …
NICE backs Pfizer’s drug for advanced kidney cancer
December 16, 2014Sales and Marketing NICE, Pfizer, Sutent, Votrient, Zytiga, axitinib, inlyta, xofigo
UK healthcare guidance body NICE has issued final draft guidance recommending Pfizer’s Inlyta for advanced kidney cancer. The draft recommendation …
Gilead sued over Sovaldi price
December 15, 2014Sales and Marketing BMS, Gilead, NICE, harvoni, hep C, septa, sofosbuvir, sovaldi
A payer is suing Gilead over the price of its hep-c drug Sovaldi in the US after spending $2.4 million …
Patient access schemes ‘lack transparency’
December 12, 2014Research and Development, Sales and Marketing Janssen, NHS, NICE, Velcade, patient access, pharma, scheme
Deals negotiated between the pharma industry and governments to allow patients access to innovative new cancer treatments risk failing because …
NICE changes insulin advice in diabetes guidelines
December 12, 2014Sales and Marketing NHS, NICE, diabetes, health survey, insulin, type 1, type 2
NICE has changed its recommendations on type 1 diabetes in adults and children, and type 2 diabetes in children, to …
Tamoxifen found to reduce breast cancer rates by 30%
December 11, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Arimidex, NICE, anastrozole, astrazenea, breast cancer, tamoxifen
A study from Queen Mary University has demonstrated that tamoxifen can reduce breast cancer rates by around 30% over 20 …
Labour to extend cancer drugs funding if elected
December 10, 2014Research and Development, Sales and Marketing CDF, Cancer, Labour, NHS, NICE, andy burnham, election
Labour has committed to continuing the Cancer Drugs Fund system under the guise of a new £330 million ‘Cancer Treatment …
NICE U-turn over Janssen arthritis drug
December 9, 2014Sales and Marketing Janssen, NHS, NICE, Stelara, arthritis, ustekinumab
NICE has reversed its decision on Janssen’s Stelara and is now recommending the active psoriatic arthritis drug. The pricing watchdog …
Government seeks stakeholder consultation over NICE
December 4, 2014Sales and Marketing ABPI, NHS, NICE, UK, emms, freeman, government, ndpb
NICE stakeholders are being asked for their views on its future as part of the government’s ongoing review into the …
NICE recommends test to reduce antibiotic use
December 3, 2014Sales and Marketing Antibiotics, GPs, NICE, UK, doctors, icl, pneumonia
NICE guidelines say GPs should use point of care blood tests to assess which patients to prescribe antibiotics for bacterial …
NICE U-turn on Roche leukaemia drug
December 2, 2014Sales and Marketing Gazyvaro, MabThera, NHS, NICE, Roche, leukaemia, obinutuzumab
NICE has reversed its decision on Roche’s chronic lymphocytic leukaemia (CLL) drug Gazyvaro only two months after rejecting the drug. …
Lundbeck’s alcohol pill given NICE approval
November 27, 2014Sales and Marketing Lundbeck, NHS, NICE, alcohol, selincro
NICE has finally approved the use of Selincro (nalmefene) in order to help people who are dependent on alcohol cut …
NHS to get world’s most expensive drug
November 27, 2014Sales and Marketing Alexion, NICE, aHUS, beauchamp, blood, eculizumab, soliris
UK health watchdog NICE has recommended Alexion’s Soliris for patients with the rare disease atypical haemolytic uremic syndrome (aHUS). Soliris …
NICE aims for earlier cancer diagnosis
November 20, 2014Sales and Marketing Cancer, England, NHS, NICE, OECD, UK, baker
NICE is updating its guidance in a bid to help doctors spot the signs and symptoms of cancer as part …
NICE wants more Xolair data
November 19, 2014Sales and Marketing Genentech, NHS, NICE, Novartis, UK, Xolair, hives, omalizumab
Novartis has been asked in draft guidance to give NICE more information before the watchdog can recommend its veteran asthma …
Latest content
FibroFind appoints Lee Borthwick as CEO
